Kyntra Bio (KYNB) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to -$13.1 million.
- Kyntra Bio's Income from Continuing Operations rose 7277.81% to -$13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.3 million, marking a year-over-year increase of 7798.47%. This contributed to the annual value of -$153.1 million for FY2024, which is 5259.68% up from last year.
- According to the latest figures from Q3 2025, Kyntra Bio's Income from Continuing Operations is -$13.1 million, which was up 7277.81% from -$13.7 million recorded in Q2 2025.
- In the past 5 years, Kyntra Bio's Income from Continuing Operations registered a high of $49.5 million during Q3 2021, and its lowest value of -$134.5 million during Q2 2021.
- In the last 5 years, Kyntra Bio's Income from Continuing Operations had a median value of -$64.3 million in 2023 and averaged -$58.2 million.
- In the last 5 years, Kyntra Bio's Income from Continuing Operations crashed by 28613.92% in 2022 and then surged by 9067.75% in 2024.
- Kyntra Bio's Income from Continuing Operations (Quarter) stood at -$134.4 million in 2021, then soared by 50.56% to -$66.5 million in 2022, then plummeted by 39.86% to -$92.9 million in 2023, then surged by 90.68% to -$8.7 million in 2024, then plummeted by 51.71% to -$13.1 million in 2025.
- Its last three reported values are -$13.1 million in Q3 2025, -$13.7 million for Q2 2025, and -$16.8 million during Q1 2025.